6-Carboxy-2-phenyl-1,3-dioxane | 178680-96-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二恶烷
• 英文名称: 6-Carboxy-2-phenyl-1,3-dioxane
• 英文别名: 2-Phenyl-1,3-dioxane-4-carboxylic acid
• CAS: 178680-96-1
• 化学式: C₁₁H₁₂O₄
• mdl: MFCD24483616
• 分子量: 208.214
• InChiKey: AWRXHWTXLRTSEO-UHFFFAOYSA-N

物化性质

• 沸点：
  387.9±42.0 °C(Predicted)
• 密度：
  1.262±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-Carboxy-2-phenyl-1,3-dioxane 、 N-(2,2-dimethoxyethyl)-6-[4-amino-3-O-benzyl-4,6-dideoxy-2-O-methyl-α-D-mannopyranosyl-(1->2)-tetrakis(4-amino-3-O-benzyl-4,6-dideoxy-α-D-mannopyranosyl)-(1->2)-(4-amino-3-O-benzyl-4,6-dideoxy-α-D-mannopyranosyl)oxy]hexanamide 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 N-(2,2-dimethoxyethyl)-6-{3-O-benzyl-4-(2,4-O-benzylidene-3-deoxy-L-glycero-tetronamido)-4,6-dideoxy-2-O-methyl-α-D-mannopyranosyl-(1->2)-tetrakis[3-O-benzyl-4-(2,4-O-benzylidene-3-deoxy-L-glycero-tetronamido)-4,6-dideoxy-α-D-mannopyranosyl...]...}...
  参考文献：
  名称：

  Studies on vaccines against cholera. Synthesis of neoglycoconjugates from the hexasaccharide determinant of Vibriocholerae O:1, serotype Ogawa, by single-point attachment or by attachment of the hapten in the form of clusters

  摘要：

  The terminal hexasaccharide of the O-antigen of Vibrio cholerae O:1, serotype Ogawa, has been synthesized in the form of a glycoside whose aglycon (linker) allows conjugation to carrier proteins by reductive amination. The conjugate obtained from direct, single-point attachment of the linker-equipped hapten to chicken serum albumin (CSA) contained seven hapten residues/CSA. A neoglycoconjugate containing the carbohydrate antigen in the form of clusters was obtained using, as a hapten subcarrier, an oligopeptide containing 16 amino groups. It was treated with a limited amount of hapten, to give a hapten-carrying subcarrier (HCS). Subsequent conjugation of HCS to CSA, using squaric acid diethyl ester as a conjugation reagent, gave a cross-linked, glycocluster conjugate containing 51% (w/w) of the carbohydrate. Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0008-6215(99)00185-8

文献信息

• Oxazolidinone derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：Syngenta Limited

  公开号：US20030144263A1

  公开（公告）日：2003-07-31

  Compounds of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, 1 wherein, for example, X is —O— or —S—; HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, Q1 and Q2 2 R 2 and R 3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5): 3 wherein Rc is, for example, R 13 CO—, R 13 SO 2 — or R 13 CS—; wherein R 13 is, for example, optionally substituted (1-10C)alkyl or R 14 C(O)O(1-6C)alkyl wherein R 14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.

  式(I)的化合物，或其药学上可接受的盐，或其体内可水解的酯， 其中，例如，X为—O—或—S—； HET是一个可选择的取代的C-连接的含有2到4个异原子（独立选择自N、O和S）的5元杂芳环； Q从Q1和Q2中选择 R2和R3独立地为氢或氟； T从一系列基团中选择，例如，一个N-连接的（完全不饱和的）5元杂芳环系统或式(TC5)的基团： 其中Rc是，例如，R13CO—，R13SO2—或R13CS—； 其中R13是，例如，可选择的取代的(1-10C)烷基或R14C(O)O(1-6C)烷基 其中R14是可选择的取代的(1-10C)烷基；这些化合物可用作抗菌剂；并描述了其制备方法和含有它们的药物组合物。
• OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：AstraZeneca UK Limited

  公开号：EP1082323A2

  公开（公告）日：2001-03-14
• US6617339B1
  申请人：——

  公开号：US6617339B1

  公开（公告）日：2003-09-09
• [EN] OXAZOLIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] COMPOSES CHIMIQUES
  申请人：——

  公开号：WO1999064417A2

  公开（公告）日：1999-12-16

  [EN] Compounds of formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein, for example, X is -O- or -S-; HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N, O and S; Q is selected from, for example, formulae (Q1) and (Q2); R<2> and R<3> are independently hydrogen or fluoro; T is selected from a range of groups, for example, an N-linked (fully unsaturated) 5-membered heteroaryl ring system or a group of formula (TC5) wherein Rc is, for example, R<13>CO-, R<13>SO2- or R<13>CS-; wherein R<13> is, for example, optionally substituted (1-10C)alkyl or R<14>C(O)O(1-6C)alkyl wherein R<14> is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.
  [FR] L'invention concerne des composés représentés par la formule (I), ou un sel pharmaceutiquement acceptable, ou un ester de ceux-ci pouvant être hydrolysé in vivo. Dans la formule, par exemple, X est -O- ou -S-; HET est un système cyclique hétéroaryle à 5 chaînons et à liaison C éventuellement substitué contenant de 2 à 4 hétéroatomes sélectionnés indépendamment dans le groupe comprenant N, O et S; Q est sélectionné, par exemple, entre (Q1) et (Q2). R<2> et R<3> sont indépendamment hydrogène ou fluoro; T est sélectionné dans le groupe comprenant, par exemple, un système cyclique hétéroaryle à 5 chaînons (complètement insaturé) à liaison N, et un groupe représenté par la formule (TC5). Dans cette formule, Rc est, par exemple, R<13>CO-, R<13>SO2- ou R<13>CS-; R<13> est, par exemple, un alkyle en 1-10C éventuellement substitué ou R<14>C(O)O(1-6C)alkyle; R<14> est un alkyle en 1-10C éventuellement substitué. Les composés sont utiles comme agents antibactériens. Des procédés de fabrication de ces composés sont décrits, ainsi que des compositions pharmaceutiques contenant ceux-ci.